These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 23661492)

  • 21. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
    Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
    Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.
    Wevers-de Boer KV; Heimans L; Visser K; Kälvesten J; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Steup-Beekman M; de Buck MP; de Sonnaville PB; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2015 Feb; 74(2):341-6. PubMed ID: 24285491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
    Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
    J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
    Güler-Yüksel M; Bijsterbosch J; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Hulsmans HM; de Beus WM; Han KH; Breedveld FC; Dijkmans BA; Allaart CF; Lems WF
    Ann Rheum Dis; 2008 Jun; 67(6):823-8. PubMed ID: 17644545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
    Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
    Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modern treatment strategies in rheumatoid arthritis.
    Hetland ML
    Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis.
    Haugeberg G; Morton S; Emery P; Conaghan PG
    Ann Rheum Dis; 2011 Jan; 70(1):184-7. PubMed ID: 20805297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
    Hejdova M; Palicka V; Kucera Z; Vlcek J
    Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
    Ikeda T; Maruyama K; Kaji H; Akagi M
    Mod Rheumatol; 2014 Jul; 24(4):671-6. PubMed ID: 24313921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study.
    Krieckaert CL; Nurmohamed MT; Wolbink G; Lems WF
    Rheumatology (Oxford); 2013 Mar; 52(3):547-53. PubMed ID: 23221326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of hand bone mineral density in early rheumatoid arthritis using dual energy X-ray absorptiometry.
    Hill CL; Schultz CG; Wu R; Chatterton BE; Cleland LG
    Int J Rheum Dis; 2010 Aug; 13(3):230-4. PubMed ID: 20704619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss.
    Hoff M; Haugeberg G; Kvien TK
    Arthritis Res Ther; 2007; 9(4):R81. PubMed ID: 17705865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.
    Chen YM; Chen HH; Huang WN; Liao TL; Chen JP; Chao WC; Lin CT; Hung WT; Hsieh CW; Hsieh TY; Chen YH; Chen DY
    PLoS One; 2017; 12(11):e0188454. PubMed ID: 29155868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of periarticular bone loss is associated with clinical remission and ACR70-Response in rheumatoid arthritis.
    Pfeil A; Nussbaum A; Renz DM; Jung C; Oelzner P; Malich A; Wolf G; Böttcher J
    Rheumatol Int; 2019 Apr; 39(4):637-645. PubMed ID: 30569216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP.
    Hetland ML; Østergaard M; Ejbjerg B; Jacobsen S; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Svendsen A; Pedersen JK; Skjødt H; Ellingsen T; Lindegaard H; Pødenphant J; Hørslev-Petersen K;
    Ann Rheum Dis; 2012 Jun; 71(6):851-6. PubMed ID: 22302316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study.
    Tada M; Inui K; Sugioka Y; Mamoto K; Okano T; Anno S; Koike T
    Rheumatol Int; 2017 Jun; 37(6):999-1005. PubMed ID: 28405825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.